Considering the role of IL-33 and the alarmin thymic stromal lymphopoietin in activating the type 2 immune response [31], a combined blockade of both cytokines may be beneficial in patients with immunological conditions such as asthma or CRSwNP. Here, TSLP is linked to asthma.